Recent Updates in the Treatment of Follicular Lymphoma and Mantle Cell Lymphoma

A panel of experts discuss recent updates including new data from ASH 2023 on the treatment of follicular lymphoma and mantle cell lymphoma as well as their clinical implications.

EP. 1: Current Treatment Options in First-line FL

December 18th 2023

Experts on follicular lymphoma discuss first-line treatment options available for patients.

EP. 2: ASH 2023 Updates on Frontline Therapies in FL

January 2nd 2024

A panel of experts review latest data from ASH 2023 on approved and emerging therapies in frontline FL.

EP. 3: Current Treatment Options in Second-line FL

January 2nd 2024

Experts on follicular lymphoma discuss second-line treatment options available for patients.

EP. 4: CAR T-cells as Third-line and Beyond Therapy for FL

January 2nd 2024

Bijal Shah, MD, discusses recent data on CAR T-cell therapy as third-line and beyond treatment for FL.

EP. 5: Bispecific T-cell Engagers as Third-line and Beyond Therapy for FL

January 10th 2024

Matthew Lunning, DO, discusses recent data on bispecific T-cell engagers as third-line and beyond therapy for FL.

EP. 6: Tazemetostat as Third-line and Beyond Therapy for FL

January 10th 2024

Peter Martin, MD, discusses recent data on tazemetostat, an EZH2 inhibitor, as third-line and beyond therapy for FL.

EP. 7: Zanubrutinib as Third-Line and Beyond Therapy for FL

January 16th 2024

Laurie Sehn, MD, discusses recent data on zanubrutinib, a BTK inhibitor, as third-line and beyond therapy for FL.

EP. 8: Choosing Bispecific T-cell Engager as Third-line and Beyond Therapy for FL

January 16th 2024

A panel of experts discuss how to choose bispecific T-cell engagers as third-line and beyond therapy for FL.

EP. 9: Choosing CAR T-cells as Third-line and Beyond Therapy for FL

January 23rd 2024

Jennifer Crombie, MD, discusses how to choose CAR T-cells as third-line and beyond therapy for FL.

EP. 10: Sequencing Immunotherapy in the Third-line and Beyond Setting for FL

January 23rd 2024

Peter Martin, MD, discusses how to sequence bispecific T-cell engagers and CAR T-cell therapies in the third-line and beyond setting for FL.

EP. 11: Unmet Needs in Treating Relapsed/Refractory FL

January 30th 2024

Laurie Sehn, MD, and Bijal Shah, MD, discuss remaining unmet needs for patients with relapsed/refractory FL.

EP. 12: Current Treatment Options in First-Line MCL

January 30th 2024

Experts on mantle cell lymphoma discuss first-line treatment options available for patients.

EP. 13: ASH 2023 Updates on Frontline Therapies in MCL

February 6th 2024

A panel of experts review latest data from ASH 2023 on approved and emerging therapies in frontline MCL.

EP. 14: Current Treatment Options in Second-line MCL

February 6th 2024

Experts on mantle cell lymphoma discuss second-line treatment options available for patients.

EP. 15: Current Treatment Options in Third-line MCL

February 13th 2024

Experts on mantle cell lymphoma discuss third-line treatment options available for patients.

EP. 16: Sequencing Therapies in the Third-Line and Beyond Setting for MCL

February 13th 2024

A panel of experts discuss how to sequence BTK inhibitors and CAR T-cell therapies in patients with MCL.

EP. 17: Future Directions and Unmet Needs in Relapsed/Refractory MCL

February 20th 2024

A panel of experts discuss future directions and remaining unmet needs for patients with relapsed/refractory MCL.